TANGO THERAPEUTICS INC. - COMMON STOCK

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

08 Mar 2022 15:57:30 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress

03 Mar 2022 08:41:35 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

02 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

24 Jan 2022 06:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the Jefferies London Healthcare Conference

11 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

09 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel

01 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

10 Aug 2021 08:00:01 By Nasdaq GlobeNewswire